{"id":"NCT01485640","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"Lurasidone Extended Use Study","officialTitle":"A Long-term, Multicenter, Open-Label, Flexible Dose Continuation Study in Subjects Who Have Completed a Prior Lurasidone Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2014-02","completion":"2014-02","firstPosted":"2011-12-05","resultsPosted":"2015-03-11","lastUpdate":"2016-11-04"},"enrollment":162,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Lurasidone","otherNames":[]}],"arms":[{"label":"Lurasidone","type":"EXPERIMENTAL"}],"summary":"This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and who may benefit from continued treatment with lurasidone.","primaryOutcome":{"measure":"Number of Subjects With Treatment Emergent AEs, SAEs or Who Discontinued Due to AEs","timeFrame":"18 months","effectByArm":[{"arm":"Lurasidone","deltaMin":63,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":46,"countries":["Canada","Colombia","Czechia","France","India","Lithuania","Romania","Russia","Serbia","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":162},"commonTop":["Headache","Diarrhoea","Influenza","Nasopharyngitis","Vomiting"]}}